Ethics, Pricing, and the Pharmaceutical Industry. Corporate Communication Faces Drug-Cost Issues
The paper investigates arguments brought forth by a big corporation in the pharmaceutical industrywhen dealing with bioethical issues. Apologetic strategies (or lack of thereof) and their discursive manifestations are investigated. More specifically, the paper focuses on press releases issued by Mylan, the pharmaceutical giant, when the company was strongly criticised in 2016 over hiking the price of one of its best-selling drugs.